CONVENIENT, COMFORTABLE AND CLINICALLY PROVEN VTE PREVENTION

Flowtron®
Active Compression System
Featuring SmartSense™ 2 with Compliance Monitoring technology

Clinical relevanceTwo Cochrane reviews, published in 2008 and 2016 respectively,
assessed the efficacy of combined mechanical and pharmacologicalprophylaxis versus single modalities in the prevention of VTE inhigh-risk patients. In the most recent meta-analysis, data from 22
randomised or controlled trials and more than 9,100 patients was
included. The selection of studies covered a wide range of patientgroups undergoing a variety of surgical procedures, including
orthopaedic, urologic, cardiothoracic, neuro, trauma, gynaecologic andgeneral surgery interventions.

Safeguarding
your patientsat risk of VTE

Both reviews concluded that the combined modalities of IPC andanticoagulants are more effective in reducing incidence of VTE thaneither modality used in isolation. While the DVT incidence rate in the
anticoagulant group was 4.23/6.2% (2008/2016), the addition of IPC
further reduced the risk to 0.65/2.9%, demonstrating an opportunity
for significant improvement in the interval of 53-85% by adding IPC topharmacological prophylaxis. These results support current guidelines
which recommend multi-modal prophylaxis in high-risk patients.6,7

Venous thromboembolism (VTE), which includes both
Deep Vein Thrombosis (DVT) and Pulmonary Embolism(PE), is a life-threatening condition that can have asignificant cost burden on acute care providers andhealthcare systems.1,2

Based on clinical evidence,
today’s guidelines recommend
Intermittent PneumaticCompression (IPC) either as aneffective standalone modality,
for patients at high risk of
bleeding, or as a combined
therapy for patients at high riskof VTE.3-7

While healthcare facilities are aware of the risk of VTE,
care providers may lack the time, training and resources
to optimally implement prevention strategies. In order tosafeguard the well-being of at-risk patients, comprehensive
prevention strategies that take into account individual
clinical needs are essential.

Understanding theburden of VTE andthe importance ofprevention
There are a number of factors that place patients at risk of
VTE. Patients undergoing surgical procedures (>30 min)have always been considered one of the most significant
risk groups for developing this condition. At the same time,awareness of other high-risk hospitalised patient groups,
such as critical care, cancer, obstetric, bariatric and stroke
patients, have steadily been increasing over recent years
with emphasised importance of prophylaxis.4,9,10

2  FLOW TRON AC TIVE COM PRESSION SYSTEM

What is IPC?
IPC is a well-established and proven type of active compression andmechanical prophylaxis, commonly used to prevent VTE. As a therapy
with a convincing evidence base and few side effects, IPC is indicatedfor use across a wide range of hospitalised patients at risk of VTE.
IPC devices consist of a pneumatic pump that inflates air into garments
wrapped around the foot, calf, thigh, or a combination of the three.
Garments may have one (uniform) or more (sequential) chambers.
By mimicking the action of the calf muscle pump that occurs during
natural ambulation, the method increases the circulation of blood in the
deep veins of the legs, helping to prevent the formation of blood clots.8

With 10 million cases
each year, VTE is a serious
condition that causes
death and disability
worldwide.1

Pulmonary embolism,
resulting from DVT,
is a potentially fatal
condition.11

While early diagnosis
and treatment may
lead to recovery, longterm complications
can result in lifelong
treatment and patient
suffering.13

In the US, it isestimated that VTE
affects 350,000 to
600,000 individuals
annually, with almost$40B spent on
treatment of hospitalacquired VTE. 2,15

VTE-related events killmore than double thenumber of people thanbreast cancer, prostatecancer, motor vehicle
accidents and AIDS
combined.9

US data states that up
to 60% of VTE cases
occur during or shortly
after hospitalisation,
making it the leading
preventable cause of
hospital death.1,12

In Europe, more than 1
million VTE cases occur
annually, resulting
in approximately
544,000 deaths and acost burden estimatedat ¤1.5-2.2B in direct
cost and ¤13.2B in total
cost.9, 14

VTE is associatedwith prolonged andrecurring hospital
stays and treatment,
causing significant
economic burden to
healthcare systems
globally.16

FLOW TRON AC TIVE COM PRESSION SYSTEM    3  The link between
compliance and clinicalefficacy in VTE prevention

Introducing the
Flowtron ActiveCompression System

When compliance is fulfilled by all those involved inpatient care, optimal clinical efficacy may be attained.

Designed to give you freedom of choice, theFlowtron system offers both uniform andsequential modes in one easy-to-use pump.

By helping to achieve compliance in patient care, theFlowtron Active Compression System and associatedservice offering is designed to support clinical efficacy.
Promotes complianceto therapy byensuring patient
comfort and risk
awareness
Patient

Flowtron
ACS900pump

Sequential
Tri Pulse
garments

Uniform
DVT
garments

SmartSense 2
Auto Garment
Recognition

SmartSense 2
Compliance
Monitoring

Non-invasive therapy that is safe,
comfortable, quiet and supported
by patient education

Caregiver
An easy-to-use
system withcompliancemonitoring andsmart alarms,
aiding caregiverintervention
and facilitating
documentation oftherapy

Clinicalefficacy

Flowtron Active Compression System is the safe,
convenient and flexible way to deliver VTE prevention
therapy.17-20 At Arjo, we have built on the Flowtron legacy
for decades, continuously improving our offering to

Facility

ensure the best possible performance of IPC therapy
across healthcare environments. We continuously strive
to make everyday tasks easier for caregivers, and enable
them to spend more time caring for their patients.

Cost-efficient therapy
supporting effective workflow
and proven outcome in asustainable manner

Flowtron ACS900 reviewed in independent evaluation

Helps ensure correct
delivery of therapy
with the convenienceof a smart pump4  FLOW TRON AC TIVE COM PRESSION SYSTEM

Supports efficient
processes, clinicalefficacy andsustainability

An evaluation conducted by the ECRI Institute, an
independent non-profit organisation focused on identifying
the safest and most effective solutions for care, rated
the Flowtron ACS900 against a comparable Sequential

Compression System in terms of performance, safety,
workflow, patient experience and cost of ownership. For
information on how to obtain a copy of the report, pleasecontact your local Arjo representative or visit www.ecri.org.

FLOW TRON AC TIVE COM PRESSION SYSTEM    5  

Enabling caregivers toprevent the preventable

Proven ease of use and safety
supporting clinical efficacy

Reduce the risk of VTE in your facility with the Flowtron ACS900
pump, featuring SmartSense 2 Automatic Garment Recognition
and Compliance Monitoring technology.

A study performed with 118 users at 32 hospitals
in 4 different countries demonstrated the clinicalapplication of the Flowtron ACS900 and Tri Pulse
garment range. User data from caregivers wascollected in areas such as patient compliance,ease of use and safety.31

The challenge
Caregivers are often under a lot of pressure in their daily workand may struggle to support the correct use and documentationof mechanical prophylaxis. The Flowtron solution is designed tohelp address caregiver challenges such as:• Lack of time and resources• Time spent on non-patient activities• Managing inventory and troubleshooting equipment• Use of multiple systems and new technologies• Need for continuous training and education• Being responsive to individual patient needs• Addressing non-compliance and documenting actual therapy

Clinical relevanceNon-compliance to therapy remains the principal barrier to
IPC effectiveness21, however compliance is not only linked tothe patient but also to caregiver adherence.
Studies have reported a misapplication of IPC devices in as
many as 50% or more of the cases observed22-24. A consistent
trend in many published studies indicates that a major
barrier to compliance is the failure of healthcare
professionals to provide IPC when mechanical prophylaxis
has been prescribed, and vigilance in reapplying garments
throughout the hospital stay22-29. This, in turn, can be
attributed to nursing workload and acuity30, resulting in lackof therapy or garment application after temporary removal28.

The case study results showed that 99.2% of the users
considered Flowtron ACS900 to be easy to use in general,
easy to operate (99.1%) and easy to clean (99.1%).

Having one pump covering all IPC therapy needs wasdeemed to contribute to ease of use by all users and to
facilitate training by 99.1% of the respondents.

The plug-and-play element was found to free up time tocare for patients by most users (94.9%) as it reduces timespent on non-patient related activities.

Regarding safety, the majority of users (94.0%)
confirmed the safety features of the pump to limit therisk of operator error and facilitate troubleshooting whenusing the Flowtron ACS900.

Flowtron
ACS900pump
A single pump that offers both uniform and sequential
compression via a variety of garment types, reducing theneed to have multiple pump models in the facility. The
easy-to-use Flowtron ACS900 makes it simple to tailor
VTE prevention with one pump covering all therapy needs.

SmartSense 2
Automatic Garment
Recognition
Arjo’s patented garment detection technology automaticallysets the correct pressure and compression cycle, without
the need for any additional user intervention. Simply attach
the snap-lock connectors to the Flowtron ACS900 pumpand the system easily and safely does the rest.
6  FLOW TRON AC TIVE COM PRESSION SYSTEM

SmartSense 2
Compliance
Monitoring
To aid concordance and facilitate tracking anddocumentation of therapy, ACS900 provides intuitive
compliance monitoring that detects garment wear-time
during IPC. It allows the pump to record and display
actual therapy as well as non-compliant time, andalert upon lack of adherence. This makes it easier for
caregivers to ensure compliance with prescribed therapy
and to enter accurate data into patient records.
The Compliance Monitoring feature was designed to:· Support clinical outcome by helping to ensure effective
delivery of IPC therapy· Assist caregiver intervention by alerting upon noncompliance to IPC therapy· Aid documentation of delivered therapy by providing
data for patient records
FLOW TRON AC TIVE COM PRESSION SYSTEM    7  

A smart system designed
to solve challenges in theclinical setting

8  FLOW TRON AC TIVE COM PRESSION SYSTEM

Smart and adaptive

Complete range of garments

Automatic garment recognition together with one-button
start make Flowtron a true plug-and-play solution that is easy
to set up and operate. Reducing the need for user intervention
by automatically identifying garments connected and setting
the correct compression profile – for safety and efficacy.18,19,31

A wide variety of garment types and sizes ensuring
effective and comfortable therapy for all patientsand clinical needs31,35,36. The system allows for any
combination of foot, calf and calf-and-thigh garments to
be used simultaneously.

Compliance monitoring

Durable and energy efficientIntuitive on-screen compliance monitoring, recording anddisplaying actual therapy as well as non-compliant timein an accurate manner. Alerts the caregiver upon garment
removal to aid concordance, and facilitates tracking anddocumentation of IPC therapy. 32,33

VTE prevention around the clock* with SmartEnergyTM
enhanced power management ensuring uninterrupted
calf therapy for a minimum of 24 hours when the pumpis not connected to a power outlet37. SmartEnergy also
contributes with reduced power consumption, CO2
emissions and cost38.

Alarms and indicators

Fixed tubesets

Advanced alarms, including visual indicators allowing
operation to be clearly seen from any direction, andreal-time pressure indication designed to limit the risk ofoperator error and potential patient harm – for safety andcaregiver peace of mind. 31

Ready for therapy at all times with fixed tubesets preventing
disconnection and loss of tubing, hence eliminating theinconvenience and cost of replacements.31

Quiet operation

Integrated cable management system

QuietConceptTM noise reduction technology significantly
reducing pump noise to minimise patient and caregiverdisruption. Allowing the ACS900 to deliver therapy in aquiet manner across all garment types, contributing to aquieter care environment. 34

Integrated cable management system aiding tubeset andpower cord management in the clinical area and duringstorage/transportation, promoting caregiver convenienceand patient safety.17-19,31*Calf: >24h / Thigh: >18h / Foot: >9h

FLOW TRON AC TIVE COM PRESSION SYSTEM    9  Featuring the latest technological advancements, Flowtron ACS900
outperforms its competition in terms of noise level34, which helps
promote patient rest, recovery and overall compliance to IPC therapy.

Clinical relevance

Hospitals can be a stressful environment for
both patients and caregivers. With the growing
amount of electrical equipment in care facilities,
and development of new medical technologies,
increasing noise and alarms from diverse
medical devices around the patient's bedsides
are becoming an issue. Results from a numberof studies39-45 confirm noise levels in clinicalsettings to be unacceptably high, consistently
and significantly exceeding recommended
thresholds. IPC devices require continuous use
to be effective in preventing VTE, and with highrates of non-adherence to prescribed therapy46,
noise should be considered a key factor inachieving patient comfort, compliance andclinical efficacy.

The World Health Organization (WHO)recommends average hospital sound levels
should not exceed 35 dB(A) in rooms where
patients are treated or observed, and 30 dB(A)in ward rooms, with a maximum of 40 dB(A)overnight47,48. Similarly, the International Noise
Council (INC) has stipulated that noise levels in
intensive care units (ICUs) should not exceed
30 dB(A) at night49-51. However, several studies
show that from 1960 to 2003, noise levels in
the ICU have increased from 57 dB to 72 dB
daytime and from 42 dB to 60 dB during night52.
A number of studies have found noise to be themost significant cause of sleep disruption in thehospital setting43,48,53-55.

Independent testing confirms Flowtron ACS900
average noise emissions to be below the 30 dB(A) limit,
irrespective of garment type in use and measured at 1m
distance as per ISO standards34.
Compared to two of the most recent and relevant
competitive devices, ACS900 measures significantly
lower for all types of compression (calf, thigh, foot,uniform, sequential), proving Flowtron ACS900 superiorboth on average and peak noise levels.
With noise emissions measuring well below thresholds
stipulated by WHO and INC as well as the US
Environmental Protection Agency (EPA)56, our aim is tocontribute to a hospital environment with less noise.

In addition to low emissions of noise with QuietConcept
technology, Flowtron ACS900 comes with the option
to select volume level or mute audible notifications
and certain alerts to adapt to care setting and user
preference.
Furthermore, the pump display and LED indicators will
dim to reduce brightness and further minimise disruption
in the hospital environment during operation. This helps
to support not only patient comfort and compliancebut also contributes to a sustainable and efficient work
environment for caregivers.

Calf Compression, 2 garments

Calf & Thigh Compression, 2 garments

50

50

40

40
Peak

dB(A)

The challenge

Proven low noise emissions
contributing to a quiet careenvironment

30

AVG

20
10
0

Peak

dB(A)

Recognising noise pollution
as a growing problem

30

AVG

20
10

Flowtron
ACS900
uniform

Flowtron
ACS900sequential

0

Sequential
Sequential
Compression Compression
Device A
Device B

Flowtron
ACS900
uniform

Flowtron
ACS900sequential

Sequential
Sequential
Compression Compression
Device A
Device B

Foot Compression, 2 garments
50

40

dB(A)

Peak

30

AVG

20
10
0

10  FLOW TRON AC TIVE COM PRESSION SYSTEM

Flowtron
ACS900
uniform

Sequential
Compression
Device A

Note 1:	Measurements taken at 1m distance in an anechoic chamber
setting as per ISO standards.
Note 2:	Competitor pump ventilation fan was not running during themeasurement.
Note 3:	Sequential Compression Device A manufactured
2019-11-13 and Device B 2021-04-23, both of the most recent
product models.
Note 4:	An increase of 10 dB(A) translates into a perceived doublingof loudness by the average listener. 57
FLOW TRON AC TIVE COM PRESSION SYSTEM    11  Addressing comfort as
key to patient compliance

Proven comfort and design
promoting effective prevention

In addition to a quiet operating pump, lightweight, breathable andvapour permeable garments promote patient compliance to therapy byhelping to prevent the build-up of heat and moisture.

With comfortable premium fabrics, making the patient more inclined to wear the
garments during therapy, Flowtron addresses the core challenge of comfort in VTE
prevention. Proven comfortable, Flowtron garments promote effective prevention andimproved patient outcomes.31,35,36,61

The challenge

Clinical relevanceThe use of IPC as a prophylactic method requires the patient to wear
garments continuously over time. This is vital to the success of IPC
in reducing the risk of VTE in the hospital environment. Guidelines
recommend therapy to take place continuously for 18-24 hours perday, and for no less than 72 hours or until the patient is fully mobile.
Mechanical prophylaxis has been suggested for as long as 10-14 days
post-operatively for patients undergoing major orthopaedic surgery. 3,58

Increasing emphasis has beenplaced on the comfort of VTE
garments in improving wear-time
which is linked with reduced VTE
event rates. 59,60

Patients may remove sleeves if they are uncomfortable, particularly
if they make the skin feel too hot, sweaty or itchy, or if the sleeves inother ways irritate the skin. Patient discomfort may increase the needfor caregivers to perform manual checks and refit sleeves to noncompliant patients that otherwise risk missing out on therapy.

A randomised, controlled trial
evaluating patient compliancewith IPC therapy, demonstrated
that a garment which was more
comfortable was worn for longer
periods.61

In the case study earlier introduced, 97.5% of the users
responded that they experience patients to comply with
Flowtron therapy.
In addition, patients were very positive with regards to thefit (98.3%) and comfort (96.5%) of the garments, andmost caregivers (99.1%) liked the anterior placement of
the single air inlet tube and felt this could help in reducing
the risk of pressure injuries.
Caregivers commented that once the device andtreatment was explained to patients, they would comply
with prescribed therapy and find the garments to be
comfortable.

Soft and breathable inner
fabric transfers heat andmoisture away from the skinthrough micro vents

12  FLOW TRON AC TIVE COM PRESSION SYSTEM

Almost all users (97.5%) who took part in the case study
indicated that they would recommend other facilities andcaregivers to use the Flowtron system.

Cushioning interior fibres
designed to aid patient
comfort

Simple and robust Velcro®
closures that help keep thegarment secureLightweight mesh outer fabrichelps prevent the build-up ofheat to keep the patient cooland dry

FLOW TRON AC TIVE COM PRESSION SYSTEM    13  

Freedom of choice with
Flowtron garments
Extensive range of foot, calf andthigh garments addressing awide variety of clinical needs andpatient types

Uniform
DVT
garments

Foot

Lightweight, breathable
fabric helps prevent thebuild-up of heat andmoisture35

Clear visual instructions
printed on the garment
for ease of use and safety
in application63

Calf

Thigh

New ergonomically andsustainably designed garment
connector promoting caregiverease of use and patient safety62

Simple and robust Velcro®
closures helping to promote
effective therapy by providing asecure and snug fit31

Garment designed to follow the natural curveof the leg, with patented wing-shaped bladderwrapping around the calf

Sequential garment range
designed for optimal
anatomical fit and enhanced
patient comfort31

Sequential
Tri Pulse
garments

Calf

Advanced Airflow Light fabric keeps theskin cool and dry by preventing heat andmoisture build-up36

ThighSingle air inlet tube positioned anteriorly on the leg away from thebony prominence, helping to reduce the risk of pressure injuries
and to promote safety with less tubing around the patient31

14  FLOW TRON AC TIVE COM PRESSION SYSTEMFLOW TRON AC TIVE COM PRESSION SYSTEM    15  

Your partner in safe and­effective VTE prevention
With over 60 years of experience, Arjo is a clinically focusedcompany that works together with healthcare professionals to better
understand the evolving needs and challenges of today’s complex
healthcare environments.

Clinical support
Designed to help you improve patient outcomes and reduce
VTE rates by promoting best practice and evidence-based
VTE prevention strategies. The goal is to improve quality ofcare and reduce cost by providing you with clinical support
to optimise device utilisation.

Our commitment to VTE prevention goes beyond acting
merely as a supplier of pumps and garments, but instead
becoming your partner in the fight against venous
thromboembolism.

Training programmes and support
We offer comprehensive training and support services
to ensure the most effective use of your VTE prevention
devices and other Arjo products. Our team not only
provides you with an in-depth understanding of VTE and
its associated complications and costs; we also provide
education on how a complete Arjo solution can help reduce
VTE rates while achieving a more efficient workflow in yourcare facility. After implementation, you will benefit fromongoing support to continuously improve workflows andpatient outcomes.

We do this by offering clinically proven prevention solutions
supporting healthcare economic value and increased
overall efficiency in the facility. This offering includes acomprehensive range of services and training programmes
designed to boost your VTE prevention strategies.

Arjo’s history
and legacy in
VTE prevention

1957: Arjo
is foundedby Swedish
entrepreneur
Arne Johansson

Rental and financial solutions
Nothing is more important than giving patients the best
possible care. Arjo offers comprehensive solutions to help
ensure you have the right equipment at the right time, andthat your facility is prepared to meet the changing needsof a diverse patient population. Our rental solutions give
you access to specialised equipment and proven therapies
to meet specific care needs – whenever and wherever
they occur. We also offer financing solutions supported
by qualified analysis to help you make the most of yourinvestments.

1973: The firstcompany todemonstratehaematologicaleffects from IPC

1998: Flowtron DVT Foot garment
range is introduced and becomesthe first foot garment on themarket with gentle inflation
compression for added comfort

2001: Introductionof Advanced Clinical
Education program,later to become Arjo
Clinical Education (ACE),
to provide customer
education on VTE and its
prevention

2007: GetingeGroup acquires
HuntleighTechnology PLC,
combining it with
Arjo to create the
ArjoHuntleigh brandArjo CareOur comprehensive service ensures that you get themost out of your equipment, and that problems areprevented before they arise. This includes a tailored service
agreement, from sourcing genuine replacement parts, tosupporting compliant processes with clear documentationof servicing records. Let us focus on the care of yourproducts, so that you can focus on caring for your patients.

2017: Arjo
becomes an
independent
publicly listedcompany

2018: Reprocessing service
launched under the Arjo
ReNu brand name in theUS, setting a clear direction
for Arjo’s sustainability andpartnership ambitions

1950

2022: Launch of SmartSense 2
with Compliance Monitoring toaid concordance and facilitate
tracking and documentation of
IPC therapy

2030
Early 1970s: The first trials of
DVT prophylaxis at Hammersmith
Hospital and Kings College
Hospital in London, leading to thedevelopment of Flowtron Aire

16  FLOW TRON AC TIVE COM PRESSION SYSTEM

Company milestone

Portfolio milestone

1979: Flowtron Aire Ltd
becomes Huntleigh,instrumental in developing
robust and clinicallyeffective IPC products

1995: Arjo isacquired byGetinge Group

2002: Flowtron Universal
becomes the first IPC pumpon the market with automatic
garment recognition andcapacity to run calf, thigh andfoot compression from thesame pump

2014: Flowtron ACS800,
later replaced by the
ACS900, becomes thefirst pump on the market
capable to deliver both
uniform and sequential
therapy

2018: Arjo acquires US based
company ReNu Medical,
specialising in non-toxic
and environmental friendly
reprocessing of single-use noninvasive medical devices

2022: Launch of ACS900
update incorporating
QuietConcept for reduced
noise level, and SmartEnergy
for lower energy consumption
and increased battery run time

FLOW TRON AC TIVE COM PRESSION SYSTEM    17  

Environmental
sustainability
Through a number of initiatives, we continuously work
to minimise the environmental impact of our products,
enabling caregivers to provide optimal care in a sustainable
manner. This includes reducing scrap and waste aswell as using more sustainable materials and processes
throughout the development, manufacturing, distribution,use, reprocessing and final disposal or recycling stages ofour products’ lifecycle.

Within VTE prevention, our acquisition of ReNu Medical*
enables us to offer non-toxic reprocessing of non-invasive
medical devices, without chemical residue or emissions. It
is part of our efforts to reduce environmental impact andmedical waste, improving the footprint of our business aswell as that of our customers, while ensuring the safety ofpatients and caregivers.

Consumes less power
and lasts longer
with improved
energy efficiency

New ergonomicallyand sustainably
designed garment
connector

Reduced power consumption
SmartEnergy technology contributes to reduced power
consumption (and associated CO2 emissions and cost)– approximately 40% lower than the main competitor

Reduced medical waste
With a more environmentally sustainable connector
design using less plastic material

Improved battery operation
New technology providing a significant increasein battery run time – a 50-100% (depending on
garment type) improvement from previous ACS900
version and up to four times better than the maincompetitor

Designed to reduce the risk of patient discomfort andmedical device-related pressure injury
With a new low-profile garment connector design

User-friendly garment
packaging with less waste
throughout the product lifecycle
New manufacturing and packaging process
Less material use and reduced scrap in garment
manufacturing and packaging

User instructions printed on polybag /Application guide printed on garment
Improved legibility, ease of use and safety

New polybag material
Higher quality, fully recyclable and easier to open

Elimination of paper format Instruction For Use (IFU)
Preservation of our environment and forests by lesspaper waste*Reprocessing currently only available in the US
18  FLOW TRON AC TIVE COM PRESSION SYSTEMFLOW TRON AC TIVE COM PRESSION SYSTEM    19  

Compression type
Sequential

Uniform

Flowtron ACS900 pump
Model

Type

Tube length

ACS900Standard

2.1m/7ft

ACS900OR (Operating Room)

4.0m/13ft

Flowtron Tri Pulse garments

Application
Application

Foot

Calf

Thigh

Item refSize

Measurement

TRP10≤ 43cm/17in

TRP20≤ 58cm/23in

TRP60L≤ 81cm/32in

TRP30≤ 71cm/28in

TRP40≤ 89cm/35in

Flowtron DVT garments

SizingApplication

Small

MediumLarge

X-large,bariatric

Item refMeasurement

DVT5≤ 36cm/14in

DVT10≤ 43cm/17in

DVT20≤ 58cm/23in

DVT60L≤ 81cm/32in

DVT30≤ 71cm/28in

DVT40≤ 89cm/35in

FG100

S-M

US (M) ≤ 7
US (F) ≤ 9
EU ≤ 40
UK ≤ 7

FG200

L-XL

US (M) ≥ 7.5
US (F) ≥ 9.5
EU ≥ 41
UK ≥ 7.5

Wall mount
Item ref:52636620  FLOW TRON AC TIVE COM PRESSION SYSTEM

Size

IV pole mount
Item ref:526359FLOW TRON ACTIVE COMPRESSION SYSTEM    21  

References

1 Jha AK, Larizgoitia I, Audera-Lopez C et al. The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf. 2013;
22:809-15.
2 Mahan CE, Borrego ME, Woersching AL et al. Venous thromboembolism: annualised United States models for total hospital-acquired and preventable
costs utilising long-term attack rates. Thromb Haemost. 2012; 108(2):291-302.
3 Guyatt GH, AKL EA, Crowther M et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis. 9th edition. American College of Chest
Physicians. Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2):7S-47S.
4 Nicolaides A, Fareed J, Kakkar A et al. Prevention and Treatment of Venous Thromboembolism - International Consensus Statement. International
Angiology. 2013; 32(2):111-260.

34 A
 rjo Data on File: Audible Test Report 100127045. ACS900 MLU. Acoustic Noise Testing of Medical Pumps. Southwest Research Institute. November 2021.
35 Ellis J. The textile properties of Deep Vein Thrombosis (DVT) garments: a factor in patient compliance with Intermittent Pneumatic Compression (IPC)
systems. Arjo Whitepaper. March 2019. Arjo.A00096.1.0.INT.EN.
36 Arjo Independent Test Data on File. Tri Pulse: water vapour resistance, thermal resistance (single plate method), drying time, liquid wicking rate andwater vapour permeability testing. September 2019. Test report E-008677/C.
37 Arjo Data on File: Battery Study Report 100127047. ACS900 MLU. November 2021.
38 Arjo Data on File: Electrical Efficiency Measurements Report 100127046. ACS900 MLU. November 2021.

5 National Institute of Health & Clinical Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep veinthrombosis or pulmonary embolism. https://www.nice.org.uk/guidance/ng89. Last accessed December 2019.

39 Elliott RM, McKinley SM, Eager D. A pilot study of sound levels in an Australian adult general intensive care unit. Noise Health. 2010 Jan-Mar; 12(46):26-36.

6 Kakkos SK, Caprini JA, Geroulakos G et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous
thromboembolism. Cochrane Database of Systematic Reviews. 2016; 9:CD005258.

41 Xie H, Kang J. The acoustic environment of intensive care wards based on long period nocturnal measurements. Noise Health. 2012 Sep-Oct;14(60):230-6.

7 Kakkos SK, Caprini JA, Geroulakos G et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous
thromboembolism in high-risk patients. Cochrane Database of Systematic Reviews. 2008; 4:CD005258.

42 Darbyshire JL, Young JD. An investigation of sound levels on intensive care units with reference to the WHO guidelines. Crit Care. 2013 Sep 3; 17(5):R187.

8 Morris RJ, Woodcock JP. Evidence based compression: Prevention of stasis and deep vein thrombosis. Annals of Surgery. 2004; 239(2):162-171.

43 Park MJ, Yoo JH, Cho BW et al. Noise in hospital rooms and sleep disturbance in hospitalized medical patients. Environ Health Toxicol. 2014 Aug 18;
29:e2014006.

9 Cohen AT, Agnelli G, Anderson FA et al. Venous thromboembolism (VTE) in Europe - The number of VTE events and associated morbidity and mortality.
Thromb Haemost. 2007; 98:756-764.

44 Scquizzato T, Gazzato A, Landoni G et al. Assessment of noise levels in the intensive care unit using Apple Watch. Crit Care. 2020 Apr 6; 24(1):130.

10 H
 eit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch
Intern Med. 2000; 160(6):809-15.
11 Know Thrombosis: Think Venous Thromboembolism. World Thrombosis Day. https://www.worldthrombosisday.org/issue/vte/. Last accessed
December 2019.
12 Heit JA, O’Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population based study.
Arch Intern Med. 2002 Jun 10; 162(11):1245-8.
13 Prevention and treatment of venous thromboembolism. Heart.org. https://www.heart.org/en/health-topics/venous-thromboembolism/preventionandtreatmentof-venous-thromboembolism-vte. Last accessed December 2019.
14 European Thrombosis & Haemostasis Alliance Consensus Statement. http://etha.eu/wp-content/uploads/2018/03/European-Thrombosis-ConsensusStatement.pdf. Last accessed December 2019.
15 Maynard G. Preventing hospital-associated venous thromboembolism: a guide for effective quality improvement. 2nd Edition. Agency for Healthcare
Research and Quality. August 2016. AHRQ Publication No. 16-0001-EF.

40 Pope D. Decibel levels and noise generators on four medical/surgical nursing units. J Clin Nurs. 2010 Sep; 19(17-18):2463-70.

45 Choiniere DB. The effects of hospital noise. Nurs Adm Q. 2010 Oct-Dec; 34(4):327-33.
46 Craigie S, Tsui JF, Agarwal A et al. Adherence to mechanical thromboprophylaxis after surgery: A systematic review and meta-analysis. Thromb Res.
2015 Oct; 136(4):723-6.
47 Berglund B, Lindvall T, Schwela DH. Guidelines for Community Noise. Geneva: World Health Organization. 1999. https://www.who.int/docstore/peh/noise/Comnoise-1.pdf. Last accessed November 2021.
48 Cunha M, Silva NRN. Hospital noise and patients' wellbeing. Procedia - Social and Behavioral Sciences. 2015; 171:246-251.
49 Liu EH, Tan S. Patients' perception of sound levels in the surgical suite. J Clin Anesth. 2000 Jun; 12(4):298-302.
50 Kam PC, Kam AC, Thompson JF. Noise pollution in the anaesthetic and intensive care environment. Anaesthesia. 1994 Nov; 49(11):982-6.
51 Delaney LJ, Currie MJ, Huang HC et al. The nocturnal acoustical intensity of the intensive care environment: an observational study. J Intensive Care.
2017 Jul 11; 5:41.
52 Busch-Vishniac IJ, West JE, Barnhill C et al. Noise levels in Johns Hopkins Hospital. J Acoust Soc Am. 2005 Dec; 118(6):3629-45.

16 G
 erotziafas GT, Papageorgiou L, Salter S et al. Updated models for VTE prediction in hospitalised medical patients. Thrombosis Research. 2018;
164(1):S62-S69.

53 Xie H, Kang J, Mills GH. Clinical review: The impact of noise on patients' sleep and the effectiveness of noise reduction strategies in intensive care units.
Crit Care. 2009; 13(2):208.

17 A
 rjo Data on File: Summative Usability Validation Report 100035519. December 2014.

54 Jones C, Dawson D. Eye masks and earplugs improve patient's perception of sleep. Nurs Crit Care. 2012 Sep-Oct; 17(5):247-54.

18 Arjo Data on File: Customer Acceptance Test (CAT) Report 100035688. June 2015.

55 Li SY, Wang TJ, Wu SFV et al. Efficacy of controlling night-time noise and activities to improve patients' sleep quality in a surgical intensive care unit.
J Clin Nurs. 2011 Feb; 20(3-4):396-407.

19 A
 rjo Data on File: Functional Test Report 100035587. December 2019.
20 A rjo Data on File: Software Test Report 100035545. December 2019.
21 Obi AT, Alvarez R, Reames BN et al. A prospective evaluation of standard versus battery-powered sequential compression devices in postsurgicalpatients. The American Journal of Surgery. 2015; 675-681.
22 E
 lpern E, Killeen K, Patel G et al. The application of intermittent pneumatic compression devices for thromboprophylaxis: an observational study foundfrequent errors in the application of these mechanical devices in ICUs. Am J Nurs. 2013; 113:30-6.
23 C
 raigie S, Tsui JF, Agarwal A et al. Adherence to mechanical thromboprophylaxis after surgery: a systematic review and meta-analysis. Thromb Res 2015;
136:723-6.
24 Tarone D. Selected long abstracts from the St. Luke's University Health Network Quality Awards Program. Int J Acad Med. 2017; 3:S176-S188.
25 Ritesma DF, Watson JM, Stiteler AP et al. Sequential compression devices in postoperative urologic patients: an observational trial and survey study
on the influence of patient and hospital factors on compliance. BMC Urology. 2013; 13:20. http://www.biomedcentral.com/1471-2490/13/20. Last
accessed July 2021.

56 Kahn DM, Cook TE, Carlisle CC et al. Identification and modification of environmental noise in an ICU setting. Chest. 1998 Aug; 114(2):535-40.
57 Cmiel CA, Karr DM, Gasser DM et al. Noise control: a nursing team's approach to sleep promotion. Am J Nurs. 2004 Feb; 104(2):40-8;quiz 48-9.
58 Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352.
59 Kucher N, Koo S, Quiroz R et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005; 352:969-977.
60 Froimson MI, Murray TG, Fazekas AF. Venous thromboembolic disease reduction with a portable pneumatic compression device. J Arthroplasty. 2009;24(2):310-316.
61 Pagella P, Cipolle M, Sacco E et al. A randomised trial to evaluate compliance in terms of patient comfort and satisfaction of two pneumatic compression
devices. Orthop Nurs. 2007; 26(3):169-74.
62 Arjo Data on File: SmartSense 2 Connector Design Report 100127048. Memo to File. November 2021.
63 Arjo Data on File: Formative Evaluation Report 100082820. December 2019.

26 Cornwell EE, Chang D, Velmahos G et al. Compliance with sequential compression device prophylaxis in at risk trauma patients: a retrospective analysis.
American Surgeon. 2002; 68(5):470-473.
27 Maxwell GL, Synan I, Hayes RP et al. Preference and compliance in postoperative thromboembolism prophylaxis among gynecologic oncology patients.
Obstet Gynecol. 2002; 100:451-5.
28 Brady D, Raingruber B, Peterson J et al. The use of knee-length versus thigh-length compression stockings and sequential compression devices. Crit Care
Nurs Q. 2007; 30:255-62.
29 Bockheim HM, McAllen KJ, Baker R et al. Mechanical prophylaxis to prevent venous thromboembolism in surgical patients: a prospective trial evaluatingcompliance. J Crit Care 2009; 24:192-6.
30 M urakami M et al. Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturised pneumatic compression device. J
Vascular Surg. 2003; 38(5):923-7.
31 Busby J, Holst K, Hansson K. User feedback on the Flowtron® ACS900 pump and Tri Pulse garment range. Arjo Whitepaper. June 2021. Arjo.
A00491.1.0.INT.EN.
32 A
 rjo Data on File: Compliance Monitoring Test Report 100126883. November 2021.
33 Arjo Data on File: Summative Evaluation Report (SER) 100116863. November 2021.

22  FLOW TRON AC TIVE COM PRESSION SYSTEMFLOW TRON AC TIVE COM PRESSION SYSTEM    23  

Flowtron
ACS900demonstration
video

Boost your VTE prevention
strategies with active
compression therapy from Arjo
Scan the QR code to view thedemonstration video. Just point yoursmartphone camera at the QR code**Android phones might need a QR reader app

Only Arjo designed parts, which are designed specifically for the purpose, should be used on the equipment and products supplied by Arjo.
As our policy is one of continuous development we reserve the right to modify designs and specifications without prior notice. ® and ™ are
trademarks belonging to the Arjo group of companies.
© Arjo, 2021
Velcro® copyright, trademarks and logos are the intellectual property of Velcro IP Holdings LLC.
At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions aredesigned to promote a safe and dignified experience through patient handling, medical beds, personal hygiene, disinfection, diagnostics, andthe prevention of pressure injuries and venous thromboembolism. With over 6000 people worldwide and 60 years caring for patients andhealthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges.
Arjo AB · Hans Michelsensgatan 10 · 211 20 Malmö · Sweden · +46 10 335 4500
www.arjo.com

Arjo.A00549.2.0.INT.EN